NEW YORK (GenomeWeb) – Novacyt said today that it has completed a €3 million ($3.3 million) private financing.

The clinical diagnostics firm will use net proceeds from the fundraising to invest in a new manufacturing facility in Camberley, UK, to accommodate increased manufacturing of Lab21 clinical laboratory products and the NOVAprep liquid-based cytology platform for cervical cancer screening.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.